BioLineRx is trading 5.04% down now at $2.64 after announcing a $3.75 million registered direct offering and concurrent private placement on August 28, 2026.
- The financing includes 1,348,921 ADSs priced at $2.78 each and warrants for up to 2,023,382 additional ADSs, raising dilution concerns.
- The offering is expected to close on or about August 31, 2026.
- The company has no earnings release until August 31, 2026, before markets open.